Metastatic Malignant Solid Neoplasm — Expanded Access Programs
Overview
Right2Hope maintains a directory of 33 expanded access programs, clinical trials, and compassionate use pathways listed for Metastatic Malignant Solid Neoplasm. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with metastatic malignant solid neoplasm programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 11 programs are currently active or recruiting, with the remaining 22 in other lifecycle stages. Sponsors actively running programs in this area include National Cancer Institute (NCI), M.D. Anderson Cancer Center, Mayo Clinic, NRG Oncology, OHSU Knight Cancer Institute, and others.
By recruiting status
Snapshot of where every Metastatic Malignant Solid Neoplasm program currently sits in its lifecycle.
- Active / Recruiting11
- Inactive22
Top sponsors
Organisations running the most Metastatic Malignant Solid Neoplasm programs in the directory.
- National Cancer Institute (NCI)14 programs
- M.D. Anderson Cancer Center8 programs
- Mayo Clinic2 programs
- NRG Oncology2 programs
- OHSU Knight Cancer Institute2 programs
- Alliance for Clinical Trials in Oncology1 program
- Northwestern University1 program
- Rahul Aggarwal1 program
- Rutgers, The State University of New Jersey1 program
- Tianhong Li1 program
Metastatic Malignant Solid Neoplasm programs (33)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Avelumab and M6620 for Treating Advanced Solid Tumors with DNA Repair Issues — M.D. Anderson Cancer Center
- Study Comparing Radiation Therapy to Usual Care for Patients with High-Risk Bone Metastases — NRG Oncology
- Study on Morning Versus Afternoon Immunotherapy for Treating Advanced or Metastatic Solid Tumors — OHSU Knight Cancer Institute
- Study on Pembrolizumab for Treating Rare Tumors That Cannot Be Surgically Removed or Have Spread — M.D. Anderson Cancer Center
- Personalized Antibody-Drug Conjugate Therapy for Advanced or Metastatic Solid Tumors Based on RNA and Protein Testing — National Cancer Institute (NCI)
- Study Comparing Longer Radiation Therapy to Usual Radiation Therapy for Cancer Spread to the Brain — NRG Oncology
- Study on Adding Copanlisib to Usual Immunotherapy for Advanced Solid Cancers with PIK3CA and PTEN Gene Changes — National Cancer Institute (NCI)
- Study on Using Nilotinib and Paclitaxel for Patients with Progressive Solid Cancers Previously Treated with Taxane Therapies — National Cancer Institute (NCI)
- Study on Whether Cancers with Specific Mutations Respond Better to the Drug Telaglenastat Hydrochloride (BeGIN Study) — National Cancer Institute (NCI)
- Study on Trametinib and Navitoclax for Treating Advanced or Metastatic Solid Tumors — National Cancer Institute (NCI)
- Study on Veliparib and Topotecan for Treating Solid Tumors, Relapsed or Resistant Ovarian Cancer, or Primary Peritoneal Cancer — National Cancer Institute (NCI)
- Study on Cancer Vaccine Labvax 3(22)-23 and GM-CSF Alone or with Pembrolizumab for Treating Advanced Adenocarcinoma — Tianhong Li
- Study on Anti-CTLA4-NF mAb, Nivolumab, and Targeted Radiation Therapy for Treating Metastatic Solid Tumors — M.D. Anderson Cancer Center
- Study on Avapritinib for Treating CKIT or PDGFRA Mutation-Positive Advanced or Metastatic Solid Tumors — M.D. Anderson Cancer Center
- Study on Axatilimab, Retifanlimab, and Paclitaxel for Treating Advanced or Metastatic Solid Tumors — OHSU Knight Cancer Institute
- Study on Ceralasertib Alone and Combined with Olaparib or Durvalumab for Patients with Solid Tumors — Rahul Aggarwal
- Study on Durvalumab Combined with Chemotherapy for Treating Advanced Solid Tumors (DURVA+ Study) — National Cancer Institute (NCI)
- Genetic Testing in Guiding Treatment for Patients with Brain Metastases — Alliance for Clinical Trials in Oncology
- Larotrectinib for Treating Solid Tumors with NTRK Gene Amplification — M.D. Anderson Cancer Center
- Study on the Effects of Talazoparib in Patients with Advanced Cancer and DNA Repair Variations — National Cancer Institute (NCI)
- Nivolumab for Treating Advanced Solid Tumors with ARID1A Mutation and CXCL13 Expression — M.D. Anderson Cancer Center
- Study on Pembrolizumab for Treating Advanced, Recurrent, or Locally Advanced Cancer with Genomic Instability — Rutgers, The State University of New Jersey
- Study on Pemetrexed for Treating Metastatic Urothelial Bladder Cancer and Other Solid Tumors with Specific Gene Changes — Northwestern University
- Personalized Vaccine with Pembrolizumab for Treating Advanced Solid Tumors — Mayo Clinic
- Phase I/II Study of NBTXR3 with Radiation and Immunotherapy for Advanced Solid Tumors — M.D. Anderson Cancer Center
- Study on Radiation Therapy for Patients with Metastatic Cancer That Has Worsened After Immunotherapy — M.D. Anderson Cancer Center
- Study Comparing Single and Fractionated Stereotactic Radiosurgery for Treating Brain Metastases — Mayo Clinic
- Study of Chemotherapy Plus Ipatasertib for People with Solid Tumors with PTEN/AKT Mutations — National Cancer Institute (NCI)
- Study on Targeted Therapy Guided by Genetic Testing for Patients with Advanced Solid Tumors — National Cancer Institute (NCI)
- Testing a New Anti-Cancer Drug Combination with Radiation for Advanced Solid Tumors and Liver Cancers — National Cancer Institute (NCI)
- Study on the Safety and Effectiveness of Combining Temozolomide and M1774 for Treating Advanced Cancer — National Cancer Institute (NCI)
- Testing the Combination of Anti-Cancer Drugs ZEN-3694 and Talazoparib in Patients with Advanced Solid Tumors (The ComBET Trial) — National Cancer Institute (NCI)
- Study on Using AMG 510 (Sotorasib) and Panitumumab for Treating KRAS G12C Mutant Solid Tumor Cancers — National Cancer Institute (NCI)
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Metastatic Malignant Solid Neoplasm to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.